Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxVaccines for Epidemic Infections and the Role of CEPIFusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureImmunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola InfectionHuman Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 HexonSafety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phasChimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques.Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.Development of vaccines against Crimean-Congo haemorrhagic fever virus.Development of replication-deficient adenovirus malaria vaccines.Chikungunya Virus Vaccines: Viral Vector-Based Approaches.Ebola Vaccination Using a DNA Vaccine Coated on PLGA-PLL/γPGA Nanoparticles Administered Using a Microneedle Patch.Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.Taxonomy proposal for Old World monkey adenoviruses: characterisation of several non-human, non-ape primate adenovirus lineages.Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.Virus vs. virus: adenovirus vectored vaccine to defeat respiratory syncytial virus.Current trends in Zika vaccine developmentDevelopment of novel vaccine vectors: Chimpanzee adenoviral vectors.Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.
P2860
Q24273364-88A10715-9885-479B-8596-AF343D6F699DQ29224804-71EBAC6B-3D42-45C0-BB9A-A8AF89E7E76BQ33586992-26566CDD-69E0-4793-ABB4-80F6619A6AF7Q34257253-6A7D5062-1C8E-4444-AEBA-CA8CE81C2C3BQ34529382-247B8A5B-4384-42C8-A18A-77893C0E50F1Q34600955-C21CBE94-139E-41EF-965B-8B773097E6A6Q34991437-E0B5A481-8062-4720-9E09-823170064EB1Q35344875-6A4A6BFD-C9F7-4D23-89DB-C5BFF6DBD37CQ35635434-76CE135D-4E00-497F-B13F-01AC3515E440Q35917501-EE60C183-FAF5-448A-8B2E-E4130F8DD92BQ36058021-46BC35EB-7F48-4859-A91C-575A842D1E98Q36258838-91D774C9-CEA7-46FD-BF14-BD22D9082023Q36347381-C55BF735-5DF7-46A0-962F-A4532F0737E5Q36463070-1FBADD22-2470-4AB9-B1BC-951D78277D97Q37499531-A98B44A1-7032-42D4-89FC-5E8672B33ECCQ37641378-4FA24092-8419-427A-9404-4411AF05F3B7Q38284700-15610E30-7DEE-4E30-B91C-58C5B40A9304Q38443390-8A89BD6B-3BAC-43EE-9377-0A1F68189893Q38688993-C0E00CEA-5210-4011-9A4C-AD10CC3CB626Q38949194-9C9AA159-5819-43A7-A500-97E2774CA881Q39128566-A8B8B2A6-6283-4098-A79E-C9A0F811BF7BQ40073524-72D4F9B1-7ECB-4AF0-B973-D25C45DA29A3Q40153269-8C838D35-0FB8-4C2F-9C2A-7FD286BFBECEQ40539269-C0F501C5-746C-498F-BFF6-7CCAF7C7B86EQ41055844-4B359E2B-D2D6-41C4-AEDC-FA4F9E67DE51Q41335764-EBA1B99A-A336-47AD-8C94-62B599EAE813Q41672361-5498E80B-90D5-42DD-A9C7-DDB2904CB49AQ41936026-86DDEEF1-1D14-40B8-B925-7F0C82190131Q42330836-1AED9DEE-4911-46A8-AE55-21EDABC11249Q42334787-844F5386-58BE-4E76-B824-12CE7043A3ABQ47558190-E3F2F28D-AF7F-4797-BD69-006F24F7C2FFQ47607374-75E5616A-21A5-4298-99F5-6AF43352BE70
P2860
Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Development of chimpanzee aden ...... emerging from clinical trials.
@en
type
label
Development of chimpanzee aden ...... emerging from clinical trials.
@en
prefLabel
Development of chimpanzee aden ...... emerging from clinical trials.
@en
P2093
P2860
P356
P1476
Development of chimpanzee aden ...... emerging from clinical trials
@en
P2093
Alfredo Nicosia
Antonella Folgori
Riccardo Cortese
Stefano Colloca
Virginia Ammendola
P2860
P304
P356
10.1586/ERV.13.15
P577
2013-04-01T00:00:00Z